Breaking News: NVO – Market Insights, Analysis & Latest Updates

Citi hires top dealmaker Jeff Stute from Perella to bolster healthcare M&A ranks

Jeff Stute joins Citigroup as vice chair for healthcare mergers, aiming to enhance the bank's market share amid declining healthcare deal volumes.

investing.com • 04/11/2024 - 14:14 PM

LLY
NVO

Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles

Americans face ongoing challenges accessing Eli Lilly and Novo Nordisk's weight-loss drugs due to supply issues, insurance hurdles, and high costs, leading many to seek cheaper compounded alternatives.

investing.com • 04/11/2024 - 11:03 AM

CTLT
NVO

EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6

EU regulators will decide by Dec. 6 on Novo Holdings' acquisition of Catalent amid concerns over competition in the weight-loss drug market.

investing.com • 04/11/2024 - 08:01 AM

Explainer-Who in the US benefits from $35 insulin?

Vice President Harris highlights insulin price cap achievements while advocacy groups point out ongoing costs and access issues for non-Medicare patients, urging broader regulatory changes.

investing.com • 30/10/2024 - 10:09 AM

LLY
NVO

Eli Lilly’s weight-loss drug Mounjaro set for Hong Kong launch - report

Eli Lilly will launch weight-loss drug Mounjaro in Hong Kong, aiming for the wider China market, amid high demand and supply challenges for such medications.

investing.com • 28/10/2024 - 08:20 AM

EU lags US and China in AI investments, Nvidia CEO says

Nvidia's CEO highlights the EU's AI investment lag, emphasizing the need for progress and the launch of a powerful supercomputer for drug discovery and digital biology.

investing.com • 23/10/2024 - 09:23 AM

LLY
NVO

US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds

Most U.S. states do not cover Novo Nordisk and Eli Lilly's weight-loss drugs in Medicaid, primarily due to cost, while spending on Medicaid is expected to rise amid declining membership.

investing.com • 23/10/2024 - 09:04 AM

Roche comes out against allowing takeover of drug manufacturer Catalent

Roche's CEO urged authorities to block Novo Nordisk's acquisition of Catalent, citing potential competition issues in the weight-loss drug market, raising concerns for smaller competitors.

investing.com • 23/10/2024 - 08:41 AM

CTLT
NVO

Citigroup promotes three bankers in healthcare M&A push

Citigroup promotes Sumit Khedekar, Nishant Jadav, and Michael Guarino to enhance its healthcare investment banking efforts as part of its growth strategy.

investing.com • 22/10/2024 - 16:45 PM

CTLT
NVO

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout

Catalent's CEO will remain post-acquisition by Novo Holdings, despite concerns from U.S. consumer groups about potential competition threats in weight-loss and gene therapies.

investing.com • 21/10/2024 - 13:23 PM

Currency